Because this workout is stim-free, theres no caffeine anhydrous, which is the main ingredient in many pre-workout supplements
Prime Therapeutics' leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years News provided by Prime Therapeutics LLC Jun 25, 2025, 10:00 ET Findings also show improved persistence with high-potency, obesity-approved GLP-1 products EAGAN, Minn., June 25, 2025 /PRNewswire/ -- Only 8% of individuals (or 1 in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from pharmacy solutions partner Prime Therapeutics LLC (Prime)
Fingers crossed this one is better." Trina Fautoux., Verified Customer "I'm on my second month of IM8, along with my significant other and we both feel more energy, more brain clarity and overall improved feeling of well-being
However, individuals with Wilson's disease, a condition affecting copper metabolism, should avoid GHK-Cu entirely
Clinical trial data shows semaglutide achieves approximately 15% body weight reduction over 68 weeks without sympathomimetic drugs
People who wonder when they start losing weight on semaglutide generally find that keto accelerates the timeline for visible body composition changes
